Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Trepel, Martin ^a   Martens, Victoria ^a   Doll, Christian ^b   Rahlff, Janina ^a   Gösch, Barbara ^a   Loges, Sonja ^a   Binder, Mascha ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPITOPE; IMMUNOGLOBULIN; LENALIDOMIDE; THALIDOMIDE; GLUTATHIONE TRANSFERASE; LIGAND; PEPTIDE; RECOMBINANT PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BLOOD CELL; BONE MARROW CELL; CELL ISOLATION; CELL LABELING; CELL SURFACE; CELL TRACKING; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MULTIPLE MYELOMA; PEPTIDE LIBRARY; POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; BLOOD; CHEMISTRY; COHORT ANALYSIS; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; PHENOTYPE; REMISSION; REPRODUCIBILITY; STEM CELL TRANSPLANTATION;

B-LYMPHOCYTES; COHORT STUDIES; EPITOPES; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOGLOBULINS; LIGANDS; MULTIPLE MYELOMA; PEPTIDE LIBRARY; PEPTIDES; PHENOTYPE; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; STEM CELL TRANSPLANTATION;

EID: 84857473351     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031998     Document Type: Article

References (51)

1. Kyle RA, Rajkumar SV, (2008) Multiple myeloma. Blood 111: 2962-2972.
2. Kyle RA, Rajkumar SV, (2004) Multiple myeloma. N Engl J Med 351: 1860-1873.
3. Turesson I, Velez R, Kristinsson SY, Landgren O, (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 28: 830-834.
4. Brennan SK, Matsui W, (2009) Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl) 87: 1079-1085.
5. Huff CA, Matsui W, (2008) Multiple myeloma cancer stem cells. J Clin Oncol 26: 2895-2900.
6. Ghosh N, Matsui W, (2009) Cancer stem cells in multiple myeloma. Cancer Lett 277: 1-7.
7. Basak GW, Carrier E, (2010) The search for multiple myeloma stem cells: the long and winding road. Biol Blood Marrow Transplant 16: 587-594.
8. Pilarski LM, Masellis-Smith A, Szczepek A, Mant MJ, Belch AR, (1996) Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma. Leuk Lymphoma 22: 375-383.
9. Berenson JR, Lichtenstein A, Hart S, Palomares D, Miller RA, (1990) Expression of shared idiotypes by paraproteins from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 75: 2107-2111.
10. Kiyotaki M, Cooper MD, Bertoli LF, Kearney JF, Kubagawa H, (1987) Monoclonal anti-Id antibodies react with varying proportions of human B lineage cells. J Immunol 138: 4150-4158.
11. Corradini P, Boccadoro M, Voena C, Pileri A, (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 178: 1091-1096.
12. Corradini P, Voena C, Omede P, Astolfi M, Boccadoro M, et al. (1993) Detection of circulating tumor cells in multiple myeloma by a PCR-based method. Leukemia 7: 1879-1882.
13. Billadeau D, Ahmann G, Greipp P, Van Ness B, (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178: 1023-1031.
14. Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, et al. (1995) In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 85: 436-447.
15. Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, et al. (1996) Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 88: 289-296.
16. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, et al. (1998) A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 92: 2844-2855.
17. Taylor BJ, Pittman JA, Seeberger K, Mant MJ, Reiman T, et al. (2002) Intraclonal homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone. Clin Cancer Res 8: 502-513.
18. Chen BJ, Epstein J, (1996) Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 87: 1972-1976.
19. Brown R, Luo XF, Gibson J, Morley A, Sykes P, et al. (1995) Idiotypic oligonucleotide probes to detect myeloma cells by mRNA in situ hybridization. Br J Haematol 90: 113-118.
20. Joshua DE, Brown RD, Luo XF, Gibson J, (1996) Circulating clonal lymphocytes in myeloma determined by mRNA in situ hybridization. Blood 88: 1125.
21. Bakkus MH, Asosingh K, Vanderkerken K, Thielemans K, Hagemeijer A, et al. (2001) Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia 15: 1127-1132.
22. Rasmussen T, Jensen L, Honore L, Johnsen HE, (2000) Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood 96: 4357-4359.
23. Rottenburger C, Kiel K, Bosing T, Cremer FW, Moldenhauer G, et al. (1999) Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol 106: 545-552.
24. Pilarski LM, Mant MJ, Belch AR, (1999) Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Leuk Lymphoma 32: 199-210.
25. Kiel K, Cremer FW, Rottenburger C, Kallmeyer C, Ehrbrecht E, et al. (1999) Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 23: 1019-1027.
26. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, et al. (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 95: 1056-1065.
27. Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, et al. (2002) Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 30: 221-228.
28. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336.
29. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, et al. (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 68: 190-197.
30. Yata K, Yaccoby S, (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18: 1891-1897.
31. Yaccoby S, Epstein J, (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94: 3576-3582.
32. McSweeney PA, Wells DA, Shults KE, Nash RA, Bensinger WI, et al. (1996) Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis. Blood 88: 622-632.
33. Pilarski LM, Giannakopoulos NV, Szczepek AJ, Masellis AM, Mant MJ, et al. (2000) In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clin Cancer Res 6: 585-596.
34. Zojer N, Schuster-Kolbe J, Assmann I, Ackermann J, Strasser K, et al. (2002) Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 117: 852-859.
35. Santonocito AM, Consoli U, Bagnato S, Milone G, Palumbo GA, et al. (2004) Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 28: 469-477.
36. Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM, (2005) Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105: 317-323.
37. Rasmussen T, Haaber J, Dahl IM, Knudsen LM, Kerndrup GB, et al. (2010) Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica 95: 1730-1737.
38. Pfeifer S, Perez-Andres M, Ludwig H, Sahota SS, Zojer N, (2011) Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. Leukemia 25: 1213-1216.
39. Taylor BJ, Kriangkum J, Pittman JA, Mant MJ, Reiman T, et al. (2008) Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny. Blood 112: 1894-1903.
40. Bertinetti C, Simon F, Zirlik K, Heining-Mikesch K, Pfeifer D, et al. (2006) Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol 77: 395-402.
41. Osterroth F, Alkan O, Mackensen A, Lindemann A, Fisch P, et al. (1999) Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J Immunol Methods 229: 141-153.
42. Wehr C, Muller F, Schuler J, Tomann T, Nitschke C, et al. (2011) Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model. Int J Cancer.
43. Jäger S, Jahnke A, Wilmes T, Adebahr S, Vogtle FN, et al. (2007) Leukemia-targeting ligands isolated from phage-display peptide libraries. Leukemia 21: 411-420.
44. Trepel M, Arap W, Pasqualini R, (2001) Modulation of the immune response by systemic targeting of antigens to lymph nodes. Cancer Research 61: 8110-8112.
45. Trepel M, Arap W, Pasqualini R, (2002) In vivo phage display and vascular heterogeneity: implications for targeted medicine. Current Opinion in Chemical Biology 6: 399-404.
46. Smith GP, Scott JK, (1993) Libraries of peptides and proteins displayed on filamentous phage. Methods in Enzymology 217: 228-257.
47. Müller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, et al. (2003) Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nature Biotechnology 21: 1040-1046.
48. Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, et al. (2007) Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol 35: 1766-1776.
49. Michelfelder S, Kohlschutter J, Skorupa A, Pfennings S, Muller O, et al. (2009) Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display Peptide libraries. PLoS One 4: e5122.
50. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M, (2006) The epitope recognized by rituximab. Blood 108: 1975-1978.
51. Binder M, Vögtle FN, Michelfelder S, Müller F, Illerhaus G, et al. (2007) Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res 67: 3518-3523.